Anrotinib is a multi-targeted small molecule targeted drug listed in 2018, with small drug side effects, and the effect should be observed at any time according to the treatment, and it is possible that the effect is poorer after six months to one year and requires switching to other regimens or chemotherapy again. Anrotinib is mainly used in the third-line treatment of non-small cell lung cancer and small cell lung cancer, but of course in other malignant tumors, such as soft tissue sarcoma also belong to the indications of Anrotinib. In addition, gastric cancer, pancreatic cancer and small cell lung cancer can also be treated with Anlotinib. The specific efficacy is not easy to determine, but can only be tried.